COPII dependent regulation of T cell alloimmunity
T 细胞同种免疫的 COPII 依赖性调节
基本信息
- 批准号:10161857
- 负责人:
- 金额:$ 58.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-05-10 至 2024-04-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAlloantigenAllogenicAutoimmunityBiological ModelsBiologyCapsid ProteinsCell physiologyCellsCellular Metabolic ProcessDataDefectDevelopmentEndoplasmic ReticulumFutureGeneticGenetic DiseasesGenetic TranscriptionGenetic TranslationGolgi ApparatusHematological DiseaseHematologyHematopoieticHematopoietic Stem Cell TransplantationHereditary DiseaseHumanImmuneImmunityIn VitroInheritedInstitutional Review BoardsKnowledgeLeadLipidsLocationMammalsMediatingMetabolicMetabolismMethodsMolecularMolecular GeneticsMolecular TargetMusMutateMutationOrgan TransplantationOutcomePathogenicityPathway interactionsPatientsPlayPost-Translational Protein ProcessingProcessProteinsResearch PersonnelRoleSamplingSolidSurgical suturesT cell regulationT-Cell DevelopmentT-LymphocyteTestingTransgenic MiceTranslationsVesicleadaptive immune responseallograft rejectioncohortcytokineextracellulargraft vs host diseasegraft vs leukemia effecthuman diseasehuman modelin vivoinsightisoimmunitymouse modelnew therapeutic targetnovelnovel strategiesparalogous geneprotein complexrare genetic disorderresponsesecretory proteinside effecttooltranscription factortype II Congenital dyserythropoietic anemia
项目摘要
ABSTRACT
T cells play a central role in adaptive immune responses. They contribute to protective as well as pathogenic
processes, such as graft versus leukemia (GVL) and graft versus host disease (GVHD) respectively, after
allogeneic hematopoietic cell (allo-HCT). The molecular mechanisms underpinning the T cell alloimmunity
are not well-understood. Identification of novel molecular targets in alloreactive T cells could lead to better
harnessing of allo-HCT, a potent therapy against many hematological and inherited diseases. Naïve T cells
upon activation by allo-antigens undergo metabolic reprogramming, upregulate transcription and translation.
Following translation from mRNA, many cellular proteins egress from the endoplasmic reticulum (ER) to
Golgi bodies (ER to Golgi pathway) for appropriate post-translational modifications prior to their transport to
final intracellular location or extracellular secretion. ER to Golgi transport is mediated by the conserved Coat
Protein Complex II (COPII) vesicles. COPII vesicles are made of heterodimers of proteins, critical amongst
which are the SEC23 proteins7. The role of sec23 dependent COPII mediated ER to Golgi transport in T cell
immunity is unknown. This proposal will address the above knowledge gap. As preliminary data, we have
generated several types of novel SEC23 transgenic mice, have an IRB approved access to rare Sec23b mutated
genetic disease patient and healthy human samples for complementary murine and human studies to test the
central hypothesis that the disruption of COPII by Sec23 mutation will reduce T-cell alloimmunity in vitro and
in vivo. The Specific Aims (SA) are:
SA 1: To determine the impact of disruption of SEC23B-dependent COPII pathway in conventional donor T
cells (Tcons) on outcomes after experimental allogeneic HCT
SA 2: To determine the molecular and genetic mechanisms of SEC23 dependent COPII vesicles in regulation
of T cell functions.
Thus our thus proposal explores a heretofore unstudied pathway, role of SEC23 dependent COPII vesicles in
immunity and represents a new direction in understanding the biology, and in identification of SEC23 as a novel
therapeutic target to mitigate T cell alloreactive responses after allo-HCT. It is grounded in novel preliminary
data, will apply state of the art methods, utilize synergistic and complementary murine and human model systems,
and is supported by co-investigators with requisite expertise. If successful, will provide fundamental mechanistic
insights into T cell allo-immunity with direct implications for allo-HCT and solid organ allo-graft rejection, and
may also have broad implications for autoimmunity, infectious immunity.
摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PAVAN REDDY其他文献
PAVAN REDDY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PAVAN REDDY', 18)}}的其他基金
COPII dependent regulation of T cell alloimmunity
T 细胞同种免疫的 COPII 依赖性调节
- 批准号:
10744487 - 财政年份:2022
- 资助金额:
$ 58.57万 - 项目类别:
Intestinal tissue intrinsic mechanisms in regulation of GI GVHD
胃肠道 GVHD 调节的肠组织内在机制
- 批准号:
10728772 - 财政年份:2022
- 资助金额:
$ 58.57万 - 项目类别:
Intestinal tissue intrinsic mechanisms in regulation of GI GVHD
胃肠道 GVHD 调节的肠组织内在机制
- 批准号:
10643802 - 财政年份:2022
- 资助金额:
$ 58.57万 - 项目类别:
Host and Microbial Metabolism in Graft versus Host Disease
移植物抗宿主病中的宿主和微生物代谢
- 批准号:
10441574 - 财政年份:2020
- 资助金额:
$ 58.57万 - 项目类别:
Crosstalk between host (IEC) mitochondria and microbial metabolism in GVHD
GVHD 中宿主 (IEC) 线粒体和微生物代谢之间的串扰
- 批准号:
10650317 - 财政年份:2020
- 资助金额:
$ 58.57万 - 项目类别:
Host and Microbial Metabolism in Graft versus Host Disease
移植物抗宿主病中的宿主和微生物代谢
- 批准号:
10650301 - 财政年份:2020
- 资助金额:
$ 58.57万 - 项目类别:
Crosstalk between host (IEC) mitochondria and microbial metabolism in GVHD
GVHD 中宿主 (IEC) 线粒体与微生物代谢之间的串扰
- 批准号:
10441579 - 财政年份:2020
- 资助金额:
$ 58.57万 - 项目类别:
相似海外基金
Operational tolerance induction by alloantigen-induced Treg cell therapy in rat lung transplantation
同种异体抗原诱导的 Treg 细胞疗法在大鼠肺移植中诱导操作耐受
- 批准号:
23K08289 - 财政年份:2023
- 资助金额:
$ 58.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Selective induction of alloantigen-specific humoral tolerance by MHC-Fc fusion proteins
MHC-Fc 融合蛋白选择性诱导同种异体抗原特异性体液耐受
- 批准号:
10432434 - 财政年份:2022
- 资助金额:
$ 58.57万 - 项目类别:
Requirements and mechanisms of alloantigen-induced cardiac allograft survival by cDC1s
cDC1同种异体抗原诱导心脏同种异体移植物存活的要求和机制
- 批准号:
10744193 - 财政年份:2022
- 资助金额:
$ 58.57万 - 项目类别:
Requirements and mechanisms of alloantigen-induced cardiac allograft survival by cDC1s
cDC1同种异体抗原诱导心脏同种异体移植物存活的要求和机制
- 批准号:
10534556 - 财政年份:2022
- 资助金额:
$ 58.57万 - 项目类别:
Selective induction of alloantigen-specific humoral tolerance by MHC-Fc fusion proteins
MHC-Fc 融合蛋白选择性诱导同种异体抗原特异性体液耐受
- 批准号:
10612453 - 财政年份:2022
- 资助金额:
$ 58.57万 - 项目类别:
Preventing GVHD by inhibition of alloantigen presentation in the gut
通过抑制肠道内同种抗原的呈现来预防 GVHD
- 批准号:
10204102 - 财政年份:2019
- 资助金额:
$ 58.57万 - 项目类别:
Preventing GVHD by inhibition of alloantigen presentation in the gut
通过抑制肠道内同种抗原的呈现来预防 GVHD
- 批准号:
10443701 - 财政年份:2019
- 资助金额:
$ 58.57万 - 项目类别:
Preventing GVHD by inhibition of alloantigen presentation in the gut
通过抑制肠道内同种抗原的呈现来预防 GVHD
- 批准号:
10737340 - 财政年份:2019
- 资助金额:
$ 58.57万 - 项目类别:
Preventing GVHD by inhibition of alloantigen presentation in the gut
通过抑制肠道内同种抗原的呈现来预防 GVHD
- 批准号:
10652374 - 财政年份:2019
- 资助金额:
$ 58.57万 - 项目类别:
Generation of alloantigen-specific Designer Platelets for diagnostic and investigative use
生成用于诊断和研究用途的同种异体抗原特异性设计血小板
- 批准号:
9005358 - 财政年份:2016
- 资助金额:
$ 58.57万 - 项目类别:














{{item.name}}会员




